cklife sciences announced on October 7, 2024, that its wholly-owned subsidiary indirectly signed a share sale agreement and a loan agreement with the buyer. Under the share sale agreement, the seller will sell 100% of the issued ordinary shares of the target company for a total price of 0.1 billion US dollars, equivalent to approximately 0.78 billion Hong Kong dollars. The buyer will pay by issuing common shares and preferred shares. In addition, the loan agreement allows the lender to provide the buyer with up to 19.5 million US dollars (approximately 152.1 million Hong Kong dollars) in loans. These transactions will result in the full ownership of WEX by the target company and the buyer's business merger, expected to accelerate the research and market entry...Show More

cklife sciences announced on October 7, 2024, that its wholly-owned subsidiary indirectly signed a share sale agreement and a loan agreement with the buyer. Under the share sale agreement, the seller will sell 100% of the issued ordinary shares of the target company for a total price of 0.1 billion US dollars, equivalent to approximately 0.78 billion Hong Kong dollars. The buyer will pay by issuing common shares and preferred shares. In addition, the loan agreement allows the lender to provide the buyer with up to 19.5 million US dollars (approximately 152.1 million Hong Kong dollars) in loans. These transactions will result in the full ownership of WEX by the target company and the buyer's business merger, expected to accelerate the research and market entry of WEX's flagship product Halneuron®. After the completion of the transaction, the seller will hold approximately 15.9% to 90.7% of the buyer's common shares. The board of directors believes that the terms of these agreements are fair and reasonable, and are in the overall interests of the company and the shareholders. According to the listing rules, these transactions are all discloseable transactions.